Latest Hotspot

Sarepta Therapeutics Gains Expanded FDA Approval for ELEVIDYS in Duchenne Muscular Dystrophy Patients Aged 4+

26 June 2024
3 min read

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced U.S. Food and Drug Administration approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory patients. 

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The FDA granted accelerated approval for non-ambulatory patients. Continued approval for non-ambulatory Duchenne patients may be contingent upon verification of clinical benefit in a confirmatory trial. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.

“Representing many years of dedicated research, development, investment and creative energy, the expansion of the ELEVIDYS label to treat Duchenne patients aged 4 and above, regardless of ambulatory status, is a defining moment for the Duchenne community. Today also stands as a watershed occasion for the promise of gene therapy and a win for science,” said Doug Ingram, president and chief executive officer, Sarepta. 

“At this pivotal moment, I want to give warm thanks to Drs. Jerry Mendell and Louise Rodino-Klapac for their dogged, 20-year pursuit of a gene therapy to treat this ruthless and life-robbing disease, to the FDA for following the scientific evidence to speed delivery of a therapy for a life-threatening rare disease to waiting patients, and to the many clinical investigators and courageous Duchenne families who have participated in the multiple studies that led to this important day.” Doug Ingram added.

Consistent with the accelerated approval pathway, Sarepta has committed to conduct and submit the results of a randomized, controlled trial to verify and confirm the clinical benefit of ELEVIDYS in patients with Duchenne muscular dystrophy who are non-ambulatory. ENVISION, a global, randomized, double-blind, placebo-controlled Phase 3 study of ELEVIDYS in non-ambulatory and older ambulatory individuals with Duchenne, is underway and intended to serve as this postmarketing requirement.

As part of a collaboration agreement signed in 2019, Sarepta is working with Roche to transform the future for the Duchenne community, enabling those living with the disease to maintain and protect their muscle function. Sarepta is responsible for regulatory approval and commercialization of ELEVIDYS in the U.S., as well as manufacturing. Roche is responsible for regulatory approvals and bringing ELEVIDYS to patients across the rest of the world.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of June 24, 2024, there are 3 investigational drugs for the micro-dystrophin target, including 2 indications, 7 R&D institutions involved, with related clinical trials reaching 10, and as many as 376 patents.

Delandistrogene moxeparvovec targets micro-dystrophin and is intended for the treatment of Muscular Dystrophy, Duchenne, as well as other nervous system diseases, congenital disorders, skin and musculoskeletal diseases, and other diseases. The approval of Delandistrogene moxeparvovec represents a significant advancement in the field of gene therapy and offers hope for patients with Duchenne muscular dystrophy and other related conditions. 

图形用户界面, 文本, 应用程序

描述已自动生成

Is Cefiderocol approved by the FDA?
Drug Insights
3 min read
Is Cefiderocol approved by the FDA?
26 June 2024
The U.S. Food and Drug Administration (FDA) approved Cefiderocol on November 14, 2019, for the treatment of complicated urinary tract infections (cUTIs) and hospital-acquired bacterial pneumonia (HABP), including ventilator-associated bacterial pneumonia (VABP).
Read →
Is Reblozyl approved by the FDA?
Drug Insights
4 min read
Is Reblozyl approved by the FDA?
26 June 2024
The U.S. Food and Drug Administration (FDA) approved Reblozyl on November 8, 2019, for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Read →
The Latest Review Provides Detailed Analysis of CAR-NK and CAR-T Cell Therapies
Hot Spotlight
8 min read
The Latest Review Provides Detailed Analysis of CAR-NK and CAR-T Cell Therapies
26 June 2024
The improved version of CAR-T therapy, CAR-NK therapy, has recently attracted considerable attention from the academic and pharmaceutical sectors due to its increased tumor-specific targeting and cytotoxicity, cost-effectiveness and easier availability of NK cells, shorter large-scale production cycles, and enhanced efficacy in treating solid tumors.
Read →
Chugai collaborates with Helsinn to promote the antiemetic drug AKYNZEO
Hot Spotlight
6 min read
Chugai collaborates with Helsinn to promote the antiemetic drug AKYNZEO
25 June 2024
On June 12, Helsinn Healthcare announced the renewal of its distribution and licensing agreement with Chugai Pharma Europe to promote AKYNZEO® (a combination drug containing netupitant and palonosetron) in the UK and Ireland.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.